Categories: NewsPharmaceutical

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2024 financial results will be released on Wednesday, November 13, 2024, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company’s website at www.fulcrumtx.com or by clicking here. Following the live webcast, an archived replay will also be available.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead program in clinical development is pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608

Staff

Recent Posts

CORRECTION FROM THE SOURCE: FloraWorks Highlights New Study Showing CBN Reverses Cognitive Decline in Aging Mice

Peer-reviewed research published in Redox Biology supports the therapeutic potential of Cannabinol (CBN) in brain…

3 hours ago

RXST INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that the…

3 hours ago

Health-E Commerce® to Showcase flexible spending account (FSA) and health savings account (HSA) Engagement Tools at 38th Annual ECFC Symposium

FSA Store® and HSA Store® will demonstrate innovative e-commerce integrations, participant education resources, and compliance…

4 hours ago

Telemedicine Market to Reach USD 393.5 Billion by 2032, Driven by 15.1% CAGR | SkyQuest Technology Consulting

The telemedicine market is anticipated to increase due to the rising incidence of chronic diseases…

4 hours ago

Anywhere powered by Linus Health™ Expands Equitable Access to Early Detection of Cognitive Impairment

Fueled by successful community and clinical screenings, Linus Health brings its AI-powered remote cognitive assessment…

4 hours ago

Siemens Healthineers Receives Frost & Sullivan’s 2025 North America Company of the Year Award for Excellence in Advanced Visualization Applications

Recognized for delivering diagnostic innovation, workflow efficiency, and enterprise imaging leadership through advanced visualization solutions…

4 hours ago